Nurix Adoptive Cell Therapy (NxACT)
Drug-Enhanced Cell Therapy to Improve Patient Outcomes
Targeted Protein Modulation can improve the expansion and quality of cell therapy products, and Nurix is pursuing its drug-enhanced cell therapies under our Nurix Adoptive Cell Therapy or NxACT approach. The first and most advanced NxACT approach is drug-enhanced tumor infiltrating lymphocytes (DeTIL). Our lead cell therapy program called DeTIL-0255 uses our proprietary ex vivo CBL-B inhibitor, NX-0255, to enhance the activity of tumor infiltrating lymphocytes.
Nurix is pursuing internal development of DeTIL-0255 as its lead DeTIL program. More on DeTIL